Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and the levels of lipoprotein A.

Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes a mendelian randomization analysis.

Lamina, C.
Kronenberg, F.
Mack, S.
Coassin, S.
Rueedi, R.
Yousri, N.A.
Seppälä, I.
Lp(a)-GWAS-Consortium (Gieger, C.)
Schönherr, S.
Forer, L.
Erhart, G.
Marques-Vidal, P.
Lp(a)-GWAS-Consortium (Ried, J.S.)
Waeber, G.
Bergmann, S.
Daehnhardt, D.
Stoeckl, A.
Raitakari, O.T.
Kähönen, M.
Lp(a)-GWAS-Consortium (Peters, A.)
Lp(a)-GWAS-Consortium (Meitinger, T.)
Lp(a)-GWAS-Consortium (Strauch, K.)
Kedenko, L.
Paulweber, B.
Lehtimäki, T.
Hunt, S.C.
Vollenweider, P.

January 2019

IMPORTANCE Genetic and epidemiologic data suggest that lipoprotein(a) (Lp[a]) is one of the stronges...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Schmidt, AF
Holmes, MV
Preiss, D
Swerdlow, DI
Denaxas, S
Fatemifar, G
Faraway, R
Finan, C
Valentine, D
Fairhurst-Hunter, Z
Hartwig, FP
Horta, BL
Hypponen, E
Power, C
Moldovan, M
Van Iperen, E
Hovingh, K
Demuth, I
Norman, K
Steinhagen-Thiessen, E
Demuth, J
Bertram, L
Lill, CM
Coassin, S
Willeit, J
Kiechl, S
Willeit, K
Mason, D
Wright, J
Morris, R
Wanamethee, G
Whincup, P
Ben-Shlomo, Y
McLachlan, S
Price, JF
Kivimaki, M
Welch, C
Sanchez-Galvez, A
Marques-Vidal, P
Nicolaides, A
Panayiotou, AG
Onland-Moret, NC
Van der Schouw, YT
Matullo, G
Fiorito, G
Guarrera, S
Sacerdote, C
Wareham, NJ
Langenberg, C
Scott, RA
Luan, J
Bobak, M
Malyutina, S
Pająk, A
Kubinova, R
Tamosiunas, A
Pikhart, H
Grarup, N
Pedersen, O
Hansen, T
Linneberg, A
Jess, T
Cooper, J
Humphries, SE
Brilliant, M
Kitchner, T
Hakonarson, H
Carrell, DS
McCarty, CA
Lester, KH
Larson, EB
Crosslin, DR
De Andrade, M
Roden, DM
Denny, JC
Carty, C
Hancock, S
Attia, J
Holliday, E
Scott, R
Schofield, P
O'Donnell, M
Yusuf, S
Chong, M
Pare, G
Van der Harst, P
Said, MA
Eppinga, RN
Verweij, N
Snieder, H
Lifelines Cohort authors
Christen, T
Mook-Kanamori, DO
ICBP Consortium
Gustafsson, S
Lind, L
Ingelsson, E
Pazoki, R
Franco, O
Hofman, A
Uitterlinden, A
Dehghan, A
Teumer, A
Baumeister, S
Dörr, M
Lerch, MM
Völker, U
Völzke, H
Ward, J
Pell, JP
Meade, T
Christophersen, IE
Maitland-van der Zee, AH
Baranova, EV
Young, R
Ford, I
Campbell, A
Padmanabhan, S
Bots, ML
Grobbee, DE
Froguel, P
Thuillier, D
Roussel, R
Bonnefond, A
Cariou, B
Smart, M
Bao, Y
Kumari, M
Mahajan, A
Hopewell, JC
Seshadri, S
METASTROKE Consortium of the ISGC
Dale, C
Costa, RPE
Ridker, PM
Chasman, DI
Reiner, AP
Ritchie, MD
Lange, LA
Cornish, AJ
Dobbins, SE
Hemminki, K
Kinnersley, B
Sanson, M
Labreche, K
Simon, M
Bondy, M
Law, P
Speedy, H
Allan, J
Li, N
Went, M
Weinhold, N
Morgan, G
Sonneveld, P
Nilsson, B
Goldschmidt, H
Sud, A
Engert, A
Hansson, M
Hemingway, H
Asselbergs, FW
Patel, RS
Keating, BJ
Sattar, N
Houlston, R
Casas, JP
Hingorani, AD

August 2019

BACKGROUND: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and ...

PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.

Marais, A David
Kim, Jae B
Wasserman, Scott M
Lambert, Gilles

January 2015

International audienceAtherosclerosis is a complex process involving the build-up of arterial plaque...

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and body mass index.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates are effects equivalent to 1 SD reduction in LDL-c levels or 1 SD reduction in plasma prote...

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and the levels of testosterone.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates are effects equivalent to 1 SD reduction in LDL-c levels or 1 SD reduction in plasma prote...

Results from drug target MR analyses to investigate the effect of lipid-lowering therapies on BMI, lipoprotein A, and testosterone.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates of effects from genetically proxied inhibition of PCSK9, NPC1L1, and HMGCR on BMI, levels ...

Study overview.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

aThe LDL-c variants were oriented to be in the LDL-c lowering direction, i.e., effect estimates in M...

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.

Si Fang
James Yarmolinsky
Dipender Gill
Caroline J Bull
Claire M Perks
PRACTICAL Consortium
George Davey Smith
Tom R Gaunt
Tom G Richardson

January 2023

BackgroundProstate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observati...

Results from MR analyses to estimate the effect of lipid-lowering therapies and risk factors on overall prostate cancer risk.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Effect estimates are odds ratios for prostate cancer per 1 SD reduction in LDL-c proxied using genet...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

Schmidt, A.F.
Holmes, M.V.
Preiss, D.
Swerdlow, D.I.
Denaxas, S.
Fatemifar, G.
Faraway, R.
Finan, C.
Valentine, D.
Fairhurst-Hunter, Z.
Hartwig, F.P.
Horta, B.L.
Hypponen, E.
Power, C.
Moldovan, M.
van Iperen, E.
Hovingh, K.
Demuth, I.
Norman, K.
Steinhagen-Thiessen, E.
Demuth, J.
Bertram, L.
Lill, C.M.
Coassin, S.
Willeit, J.
Kiechl, S.
Willeit, K.
Mason, D.
Wright, J.
Morris, R.
Wanamethee, G.
Whincup, P.
Ben-Shlomo, Y.
McLachlan, S.
Price, J.F.
Kivimaki, M.
Welch, C.
Sanchez-Galvez, A.
Marques-Vidal, P.
Nicolaides, A.
Panayiotou, A.G.
Onland-Moret, N.C.
van der Schouw, Y.T.
Matullo, G.
Fiorito, G.
Guarrera, S.
Sacerdote, C.
Wareham, N.J.
Langenberg, C.
Scott, R.A.
Luan, J.
Bobak, M.
Malyutina, S.
Pająk, A.
Kubinova, R.
Tamosiunas, A.
Pikhart, H.
Grarup, N.
Pedersen, O.
Hansen, T.
Linneberg, A.
Jess, T.
Cooper, J.
Humphries, S.E.
Brilliant, M.
Kitchner, T.
Hakonarson, H.
Carrell, D.S.
McCarty, C.A.
Lester, K.H.
Larson, E.B.
Crosslin, D.R.
de Andrade, M.
Roden, D.M.
Denny, J.C.
Carty, C.
Hancock, S.
Attia, J.
Holliday, E.
Scott, R.
Schofield, P.
O'Donnell, M.
Yusuf, S.
Chong, M.
Pare, G.
van der Harst, P.
Said, M.A.
Eppinga, R.N.
Verweij, N.
Snieder, H.
Christen, T.
Mook-Kanamori, D.O.
Gustafsson, S.
Lind, L.
Ingelsson, E.
Pazoki, R.
Franco, O.
Hofman, A.
Uitterlinden, A.
Dehghan, A.
Teumer, A.
Baumeister, S.
Dörr, M.
Lerch, M.M.
Völker, U.
Völzke, H.
Ward, J.
Pell, J.P.
Meade, T.
Christophersen, I.E.
Maitland-van der Zee, A.H.
Baranova, E.V.
Young, R.
Ford, I.
Campbell, A.
Padmanabhan, S.
Bots, M.L.
Grobbee, D.E.
Froguel, P.
Thuillier, D.
Roussel, R.
Bonnefond, A.
Cariou, B.
Smart, M.
Bao, Y.
Kumari, M.
Mahajan, A.
Hopewell, J.C.
Seshadri, S.
Dale, C.
Costa, RPE
Ridker, P.M.
Chasman, D.I.
Reiner, A.P.
Ritchie, M.D.
Lange, L.A.
Cornish, A.J.
Dobbins, S.E.
Hemminki, K.
Kinnersley, B.
Sanson, M.
Labreche, K.
Simon, M.
Bondy, M.
Law, P.
Speedy, H.
Allan, J.
Li, N.
Went, M.
Weinhold, N.
Morgan, G.
Sonneveld, P.
Nilsson, B.
Goldschmidt, H.
Sud, A.
Engert, A.
Hansson, M.
Hemingway, H.
Asselbergs, F.W.
Patel, R.S.
Keating, B.J.
Sattar, N.
Houlston, R.
Casas, J.P.
Hingorani, A.D.

October 2019

We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...

Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies : A mendelian randomization analysis

Burgess, Stephen
Ference, Brian A.
Staley, James R.
Freitag, Daniel F.
Mason, Amy M.
Nielsen, Sune F.
Willeit, Peter
Young, Robin
Surendran, Praveen
Karthikeyan, Savita
Bolton, Thomas R.
Peters, James E.
Kamstrup, Pia
Tybjærg-Hansen, Anne
Benn, Marianne
Langsted, Anne
Schnohr, Peter
Vedel-Krogh, Signe
Kobylecki, Camilla J.
Ford, Ian
Packard, Chris
Trompet, Stella
Jukema, J. Wouter
Sattar, Naveed
Di Angelantonio, Emanuele
Saleheen, Danish
Howson, Joanna M.M.
Nordestgaard, Børge G.
Butterworth, Adam S.
Danesh, John
Bargess, Stephen
Overvad, Kim
Tjønneland, Anne
Clavel-Chapelon, Francoise
Kaaks, Rudolf
Boeing, Heiner
Trichopoulou, Antonia
Ferrari, Pietro
Palli, Domenico
Krogh, Vittorio
Panico, Salvatore
Tumino, Rosario
Matullo, Giuseppe
Boer, Jolanda
Van Der Schouw, Yvonne
Weiderpass, Elisabete
Quiros, J. Ramon
Sánchez, María José
Navarro, Carmen
Moreno-Iribas, Conchi
Arriola, Larraitz
Melander, Olle
Wennberg, Patrik
Wareham, Nicholas J.
Key, Timothy J.
Riboli, Elio

July 2018

IMPORTANCE Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally assoc...

LPA VARIANTS, RISK OF CORONARY DISEASE, AND ESTIMATED CLINICAL BENEFIT OF LIPOPROTEIN(A) LOWERING THERAPIES: A MENDELIAN RANDOMIZATION ANALYSIS

Ference, BA
Burgess, Stephen
Staley, JR
Freitag, DF
Mason, Amy
Nielsen, SF
Willeit, P
Young, R
Surendran, Praveen
Karthikeyan, Savita
Bolton, Thomas
Peters, JE
Kamstrup, PR
Tybjaerg-Hansen, A
Benn, M
Langsted, A
Schnohr, P
Vedel-Krogh, S
Kobylecki, CJ
Ford, I
Packard, C
Trompet, S
Jukema, JW
Sattar, N
Di Angelantonio, Emanuele
Saleheen, D
Howson, Joanna
Nordestgaard, BG
Butterworth, Adam
Danesh, John
Consor, CHD Exome
Consorti, EPIC-CVD

August 2018

Importance: Human genetic studies have indicated that plasma lipoprotein(a) [Lp(a)] is causally ass...

Association of LPA variants with risk of coronary disease and the implications for Lipoprotein(a)-lowering therapies: a mendelian randomization analysis

Burgess, S
Ference, BA
Staley, JR
Freitag, DF
Mason, AM
Nielsen, SF
Willeit, P
Young, R
Surendran, P
Karthikeyan, S
Bolton, TR
Peters, JE
Kamstrup, PR
Tybjærg-Hansen, A
Benn, M
Langsted, A
Schnohr, P
Vedel-Krogh, S
Kobylecki, CJ
Ford, I
Packard, C
Trompet, S
Jukema, JW
Sattar, N
Di Angelantonio, E
Saleheen, D
Howson, JMM
Nordestgaard, BG
Butterworth, AS
Danesh, J
Key, T
European Prospective Investigation Into Cancer And Nutrition-Cardiovascular Disease (EPIC-CVD) Consortium

January 2018

Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally associated with ...

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

Troutt Jason S
Konrad Robert J
Cao Guoqing

February 2011

Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.

Burgess, Stephen
Ference, Brian
Staley, James
Freitag, Daniel F
Mason, Amy
Nielsen, Sune F
Willeit, Peter
Young, Robin
Surendran, Praveen
Karthikeyan, Savita
Bolton, Thomas
Peters, James
Kamstrup, Pia R
Tybjærg-Hansen, Anne
Benn, Marianne
Langsted, Anne
Schnohr, Peter
Vedel-Krogh, Signe
Kobylecki, Camilla J
Ford, Ian
Packard, Chris
Trompet, Stella
Jukema, J Wouter
Sattar, Naveed
Di Angelantonio, Emanuele
Saleheen, Danish
Howson, Joanna
Nordestgaard, Børge G
Butterworth, Adam
Danesh, John
European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium

July 2018

Importance: Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally asso...

Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes a mendelian randomization analysis.

Lamina, C.
Kronenberg, F.
Mack, S.
Coassin, S.
Rueedi, R.
Yousri, N.A.
Seppälä, I.
Lp(a)-GWAS-Consortium (Gieger, C.)
Schönherr, S.
Forer, L.
Erhart, G.
Marques-Vidal, P.
Lp(a)-GWAS-Consortium (Ried, J.S.)
Waeber, G.
Bergmann, S.
Daehnhardt, D.
Stoeckl, A.
Raitakari, O.T.
Kähönen, M.
Lp(a)-GWAS-Consortium (Peters, A.)
Lp(a)-GWAS-Consortium (Meitinger, T.)
Lp(a)-GWAS-Consortium (Strauch, K.)
Kedenko, L.
Paulweber, B.
Lehtimäki, T.
Hunt, S.C.
Vollenweider, P.

January 2019

IMPORTANCE Genetic and epidemiologic data suggest that lipoprotein(a) (Lp[a]) is one of the stronges...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Schmidt, AF
Holmes, MV
Preiss, D
Swerdlow, DI
Denaxas, S
Fatemifar, G
Faraway, R
Finan, C
Valentine, D
Fairhurst-Hunter, Z
Hartwig, FP
Horta, BL
Hypponen, E
Power, C
Moldovan, M
Van Iperen, E
Hovingh, K
Demuth, I
Norman, K
Steinhagen-Thiessen, E
Demuth, J
Bertram, L
Lill, CM
Coassin, S
Willeit, J
Kiechl, S
Willeit, K
Mason, D
Wright, J
Morris, R
Wanamethee, G
Whincup, P
Ben-Shlomo, Y
McLachlan, S
Price, JF
Kivimaki, M
Welch, C
Sanchez-Galvez, A
Marques-Vidal, P
Nicolaides, A
Panayiotou, AG
Onland-Moret, NC
Van der Schouw, YT
Matullo, G
Fiorito, G
Guarrera, S
Sacerdote, C
Wareham, NJ
Langenberg, C
Scott, RA
Luan, J
Bobak, M
Malyutina, S
Pająk, A
Kubinova, R
Tamosiunas, A
Pikhart, H
Grarup, N
Pedersen, O
Hansen, T
Linneberg, A
Jess, T
Cooper, J
Humphries, SE
Brilliant, M
Kitchner, T
Hakonarson, H
Carrell, DS
McCarty, CA
Lester, KH
Larson, EB
Crosslin, DR
De Andrade, M
Roden, DM
Denny, JC
Carty, C
Hancock, S
Attia, J
Holliday, E
Scott, R
Schofield, P
O'Donnell, M
Yusuf, S
Chong, M
Pare, G
Van der Harst, P
Said, MA
Eppinga, RN
Verweij, N
Snieder, H
Lifelines Cohort authors
Christen, T
Mook-Kanamori, DO
ICBP Consortium
Gustafsson, S
Lind, L
Ingelsson, E
Pazoki, R
Franco, O
Hofman, A
Uitterlinden, A
Dehghan, A
Teumer, A
Baumeister, S
Dörr, M
Lerch, MM
Völker, U
Völzke, H
Ward, J
Pell, JP
Meade, T
Christophersen, IE
Maitland-van der Zee, AH
Baranova, EV
Young, R
Ford, I
Campbell, A
Padmanabhan, S
Bots, ML
Grobbee, DE
Froguel, P
Thuillier, D
Roussel, R
Bonnefond, A
Cariou, B
Smart, M
Bao, Y
Kumari, M
Mahajan, A
Hopewell, JC
Seshadri, S
METASTROKE Consortium of the ISGC
Dale, C
Costa, RPE
Ridker, PM
Chasman, DI
Reiner, AP
Ritchie, MD
Lange, LA
Cornish, AJ
Dobbins, SE
Hemminki, K
Kinnersley, B
Sanson, M
Labreche, K
Simon, M
Bondy, M
Law, P
Speedy, H
Allan, J
Li, N
Went, M
Weinhold, N
Morgan, G
Sonneveld, P
Nilsson, B
Goldschmidt, H
Sud, A
Engert, A
Hansson, M
Hemingway, H
Asselbergs, FW
Patel, RS
Keating, BJ
Sattar, N
Houlston, R
Casas, JP
Hingorani, AD

August 2019

BACKGROUND: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and ...

PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.

Marais, A David
Kim, Jae B
Wasserman, Scott M
Lambert, Gilles

January 2015

International audienceAtherosclerosis is a complex process involving the build-up of arterial plaque...

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and body mass index.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates are effects equivalent to 1 SD reduction in LDL-c levels or 1 SD reduction in plasma prote...

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and the levels of testosterone.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates are effects equivalent to 1 SD reduction in LDL-c levels or 1 SD reduction in plasma prote...

Results from drug target MR analyses to investigate the effect of lipid-lowering therapies on BMI, lipoprotein A, and testosterone.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates of effects from genetically proxied inhibition of PCSK9, NPC1L1, and HMGCR on BMI, levels ...

Study overview.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

aThe LDL-c variants were oriented to be in the LDL-c lowering direction, i.e., effect estimates in M...

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.

Si Fang
James Yarmolinsky
Dipender Gill
Caroline J Bull
Claire M Perks
PRACTICAL Consortium
George Davey Smith
Tom R Gaunt
Tom G Richardson

January 2023

BackgroundProstate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observati...

Results from MR analyses to estimate the effect of lipid-lowering therapies and risk factors on overall prostate cancer risk.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Effect estimates are odds ratios for prostate cancer per 1 SD reduction in LDL-c proxied using genet...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

Schmidt, A.F.
Holmes, M.V.
Preiss, D.
Swerdlow, D.I.
Denaxas, S.
Fatemifar, G.
Faraway, R.
Finan, C.
Valentine, D.
Fairhurst-Hunter, Z.
Hartwig, F.P.
Horta, B.L.
Hypponen, E.
Power, C.
Moldovan, M.
van Iperen, E.
Hovingh, K.
Demuth, I.
Norman, K.
Steinhagen-Thiessen, E.
Demuth, J.
Bertram, L.
Lill, C.M.
Coassin, S.
Willeit, J.
Kiechl, S.
Willeit, K.
Mason, D.
Wright, J.
Morris, R.
Wanamethee, G.
Whincup, P.
Ben-Shlomo, Y.
McLachlan, S.
Price, J.F.
Kivimaki, M.
Welch, C.
Sanchez-Galvez, A.
Marques-Vidal, P.
Nicolaides, A.
Panayiotou, A.G.
Onland-Moret, N.C.
van der Schouw, Y.T.
Matullo, G.
Fiorito, G.
Guarrera, S.
Sacerdote, C.
Wareham, N.J.
Langenberg, C.
Scott, R.A.
Luan, J.
Bobak, M.
Malyutina, S.
Pająk, A.
Kubinova, R.
Tamosiunas, A.
Pikhart, H.
Grarup, N.
Pedersen, O.
Hansen, T.
Linneberg, A.
Jess, T.
Cooper, J.
Humphries, S.E.
Brilliant, M.
Kitchner, T.
Hakonarson, H.
Carrell, D.S.
McCarty, C.A.
Lester, K.H.
Larson, E.B.
Crosslin, D.R.
de Andrade, M.
Roden, D.M.
Denny, J.C.
Carty, C.
Hancock, S.
Attia, J.
Holliday, E.
Scott, R.
Schofield, P.
O'Donnell, M.
Yusuf, S.
Chong, M.
Pare, G.
van der Harst, P.
Said, M.A.
Eppinga, R.N.
Verweij, N.
Snieder, H.
Christen, T.
Mook-Kanamori, D.O.
Gustafsson, S.
Lind, L.
Ingelsson, E.
Pazoki, R.
Franco, O.
Hofman, A.
Uitterlinden, A.
Dehghan, A.
Teumer, A.
Baumeister, S.
Dörr, M.
Lerch, M.M.
Völker, U.
Völzke, H.
Ward, J.
Pell, J.P.
Meade, T.
Christophersen, I.E.
Maitland-van der Zee, A.H.
Baranova, E.V.
Young, R.
Ford, I.
Campbell, A.
Padmanabhan, S.
Bots, M.L.
Grobbee, D.E.
Froguel, P.
Thuillier, D.
Roussel, R.
Bonnefond, A.
Cariou, B.
Smart, M.
Bao, Y.
Kumari, M.
Mahajan, A.
Hopewell, J.C.
Seshadri, S.
Dale, C.
Costa, RPE
Ridker, P.M.
Chasman, D.I.
Reiner, A.P.
Ritchie, M.D.
Lange, L.A.
Cornish, A.J.
Dobbins, S.E.
Hemminki, K.
Kinnersley, B.
Sanson, M.
Labreche, K.
Simon, M.
Bondy, M.
Law, P.
Speedy, H.
Allan, J.
Li, N.
Went, M.
Weinhold, N.
Morgan, G.
Sonneveld, P.
Nilsson, B.
Goldschmidt, H.
Sud, A.
Engert, A.
Hansson, M.
Hemingway, H.
Asselbergs, F.W.
Patel, R.S.
Keating, B.J.
Sattar, N.
Houlston, R.
Casas, J.P.
Hingorani, A.D.

October 2019

We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...

Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies : A mendelian randomization analysis

Burgess, Stephen
Ference, Brian A.
Staley, James R.
Freitag, Daniel F.
Mason, Amy M.
Nielsen, Sune F.
Willeit, Peter
Young, Robin
Surendran, Praveen
Karthikeyan, Savita
Bolton, Thomas R.
Peters, James E.
Kamstrup, Pia
Tybjærg-Hansen, Anne
Benn, Marianne
Langsted, Anne
Schnohr, Peter
Vedel-Krogh, Signe
Kobylecki, Camilla J.
Ford, Ian
Packard, Chris
Trompet, Stella
Jukema, J. Wouter
Sattar, Naveed
Di Angelantonio, Emanuele
Saleheen, Danish
Howson, Joanna M.M.
Nordestgaard, Børge G.
Butterworth, Adam S.
Danesh, John
Bargess, Stephen
Overvad, Kim
Tjønneland, Anne
Clavel-Chapelon, Francoise
Kaaks, Rudolf
Boeing, Heiner
Trichopoulou, Antonia
Ferrari, Pietro
Palli, Domenico
Krogh, Vittorio
Panico, Salvatore
Tumino, Rosario
Matullo, Giuseppe
Boer, Jolanda
Van Der Schouw, Yvonne
Weiderpass, Elisabete
Quiros, J. Ramon
Sánchez, María José
Navarro, Carmen
Moreno-Iribas, Conchi
Arriola, Larraitz
Melander, Olle
Wennberg, Patrik
Wareham, Nicholas J.
Key, Timothy J.
Riboli, Elio

July 2018

IMPORTANCE Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally assoc...

LPA VARIANTS, RISK OF CORONARY DISEASE, AND ESTIMATED CLINICAL BENEFIT OF LIPOPROTEIN(A) LOWERING THERAPIES: A MENDELIAN RANDOMIZATION ANALYSIS

Ference, BA
Burgess, Stephen
Staley, JR
Freitag, DF
Mason, Amy
Nielsen, SF
Willeit, P
Young, R
Surendran, Praveen
Karthikeyan, Savita
Bolton, Thomas
Peters, JE
Kamstrup, PR
Tybjaerg-Hansen, A
Benn, M
Langsted, A
Schnohr, P
Vedel-Krogh, S
Kobylecki, CJ
Ford, I
Packard, C
Trompet, S
Jukema, JW
Sattar, N
Di Angelantonio, Emanuele
Saleheen, D
Howson, Joanna
Nordestgaard, BG
Butterworth, Adam
Danesh, John
Consor, CHD Exome
Consorti, EPIC-CVD

August 2018

Importance: Human genetic studies have indicated that plasma lipoprotein(a) [Lp(a)] is causally ass...

Association of LPA variants with risk of coronary disease and the implications for Lipoprotein(a)-lowering therapies: a mendelian randomization analysis

Burgess, S
Ference, BA
Staley, JR
Freitag, DF
Mason, AM
Nielsen, SF
Willeit, P
Young, R
Surendran, P
Karthikeyan, S
Bolton, TR
Peters, JE
Kamstrup, PR
Tybjærg-Hansen, A
Benn, M
Langsted, A
Schnohr, P
Vedel-Krogh, S
Kobylecki, CJ
Ford, I
Packard, C
Trompet, S
Jukema, JW
Sattar, N
Di Angelantonio, E
Saleheen, D
Howson, JMM
Nordestgaard, BG
Butterworth, AS
Danesh, J
Key, T
European Prospective Investigation Into Cancer And Nutrition-Cardiovascular Disease (EPIC-CVD) Consortium

January 2018

Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally associated with ...

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

Troutt Jason S
Konrad Robert J
Cao Guoqing

February 2011

Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.

Burgess, Stephen
Ference, Brian
Staley, James
Freitag, Daniel F
Mason, Amy
Nielsen, Sune F
Willeit, Peter
Young, Robin
Surendran, Praveen
Karthikeyan, Savita
Bolton, Thomas
Peters, James
Kamstrup, Pia R
Tybjærg-Hansen, Anne
Benn, Marianne
Langsted, Anne
Schnohr, Peter
Vedel-Krogh, Signe
Kobylecki, Camilla J
Ford, Ian
Packard, Chris
Trompet, Stella
Jukema, J Wouter
Sattar, Naveed
Di Angelantonio, Emanuele
Saleheen, Danish
Howson, Joanna
Nordestgaard, Børge G
Butterworth, Adam
Danesh, John
European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium

July 2018

Importance: Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally asso...

Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes a mendelian randomization analysis.

Lamina, C.
Kronenberg, F.
Mack, S.
Coassin, S.
Rueedi, R.
Yousri, N.A.
Seppälä, I.
Lp(a)-GWAS-Consortium (Gieger, C.)
Schönherr, S.
Forer, L.
Erhart, G.
Marques-Vidal, P.
Lp(a)-GWAS-Consortium (Ried, J.S.)
Waeber, G.
Bergmann, S.
Daehnhardt, D.
Stoeckl, A.
Raitakari, O.T.
Kähönen, M.
Lp(a)-GWAS-Consortium (Peters, A.)
Lp(a)-GWAS-Consortium (Meitinger, T.)
Lp(a)-GWAS-Consortium (Strauch, K.)
Kedenko, L.
Paulweber, B.
Lehtimäki, T.
Hunt, S.C.
Vollenweider, P.

January 2019

IMPORTANCE Genetic and epidemiologic data suggest that lipoprotein(a) (Lp[a]) is one of the stronges...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Schmidt, AF
Holmes, MV
Preiss, D
Swerdlow, DI
Denaxas, S
Fatemifar, G
Faraway, R
Finan, C
Valentine, D
Fairhurst-Hunter, Z
Hartwig, FP
Horta, BL
Hypponen, E
Power, C
Moldovan, M
Van Iperen, E
Hovingh, K
Demuth, I
Norman, K
Steinhagen-Thiessen, E
Demuth, J
Bertram, L
Lill, CM
Coassin, S
Willeit, J
Kiechl, S
Willeit, K
Mason, D
Wright, J
Morris, R
Wanamethee, G
Whincup, P
Ben-Shlomo, Y
McLachlan, S
Price, JF
Kivimaki, M
Welch, C
Sanchez-Galvez, A
Marques-Vidal, P
Nicolaides, A
Panayiotou, AG
Onland-Moret, NC
Van der Schouw, YT
Matullo, G
Fiorito, G
Guarrera, S
Sacerdote, C
Wareham, NJ
Langenberg, C
Scott, RA
Luan, J
Bobak, M
Malyutina, S
Pająk, A
Kubinova, R
Tamosiunas, A
Pikhart, H
Grarup, N
Pedersen, O
Hansen, T
Linneberg, A
Jess, T
Cooper, J
Humphries, SE
Brilliant, M
Kitchner, T
Hakonarson, H
Carrell, DS
McCarty, CA
Lester, KH
Larson, EB
Crosslin, DR
De Andrade, M
Roden, DM
Denny, JC
Carty, C
Hancock, S
Attia, J
Holliday, E
Scott, R
Schofield, P
O'Donnell, M
Yusuf, S
Chong, M
Pare, G
Van der Harst, P
Said, MA
Eppinga, RN
Verweij, N
Snieder, H
Lifelines Cohort authors
Christen, T
Mook-Kanamori, DO
ICBP Consortium
Gustafsson, S
Lind, L
Ingelsson, E
Pazoki, R
Franco, O
Hofman, A
Uitterlinden, A
Dehghan, A
Teumer, A
Baumeister, S
Dörr, M
Lerch, MM
Völker, U
Völzke, H
Ward, J
Pell, JP
Meade, T
Christophersen, IE
Maitland-van der Zee, AH
Baranova, EV
Young, R
Ford, I
Campbell, A
Padmanabhan, S
Bots, ML
Grobbee, DE
Froguel, P
Thuillier, D
Roussel, R
Bonnefond, A
Cariou, B
Smart, M
Bao, Y
Kumari, M
Mahajan, A
Hopewell, JC
Seshadri, S
METASTROKE Consortium of the ISGC
Dale, C
Costa, RPE
Ridker, PM
Chasman, DI
Reiner, AP
Ritchie, MD
Lange, LA
Cornish, AJ
Dobbins, SE
Hemminki, K
Kinnersley, B
Sanson, M
Labreche, K
Simon, M
Bondy, M
Law, P
Speedy, H
Allan, J
Li, N
Went, M
Weinhold, N
Morgan, G
Sonneveld, P
Nilsson, B
Goldschmidt, H
Sud, A
Engert, A
Hansson, M
Hemingway, H
Asselbergs, FW
Patel, RS
Keating, BJ
Sattar, N
Houlston, R
Casas, JP
Hingorani, AD

August 2019

BACKGROUND: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and ...

PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.

Marais, A David
Kim, Jae B
Wasserman, Scott M
Lambert, Gilles

January 2015

International audienceAtherosclerosis is a complex process involving the build-up of arterial plaque...

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and the levels of lipoprotein A.

Abstract

Extracted data

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and the levels of lipoprotein A.

Abstract

Extracted data

Related items

Related items